Core Viewpoint - The increasing prevalence of chronic diseases in China, driven by an aging population and changing lifestyles, has transformed these conditions from "medical events" to "everyday realities," highlighting a significant public health challenge [1][2]. Group 1: Current Challenges in Chronic Disease Management - Chronic disease prevention and control in China faces a "high incidence, high mortality, high economic burden" and "low screening, low treatment, low compliance" dilemma, with 91% of deaths attributed to chronic non-communicable diseases like cardiovascular diseases and diabetes [1]. - Despite ongoing efforts in chronic disease management, there is a growing disconnect between evolving patient needs and the resources allocated to address these needs, leading to a new set of challenges in chronic disease prevention and treatment [2]. Group 2: Clinical Insights and Treatment Gaps - Many patients with chronic diseases experience treatment failures, with over 85% of chronic disease patients exhibiting comorbid conditions, necessitating a shift towards integrated management approaches [3]. - The rising comorbidity rates among chronic diseases, such as the overlap between cardiovascular and respiratory diseases, underscore the need for comprehensive treatment strategies [3]. Group 3: Innovative Approaches by Pharmaceutical Companies - Pharmaceutical companies like AstraZeneca are focusing on breaking through treatment bottlenecks by developing innovative therapies and comprehensive treatment plans that address the interconnected nature of chronic diseases [4]. - AstraZeneca has presented over 80 studies at major international conferences, targeting cardiovascular, renal, metabolic, respiratory, and autoimmune diseases, aiming to provide new treatment insights and improve patient outcomes [4]. Group 4: Product Development and Pipeline - AstraZeneca's portfolio includes over 10 innovative drugs in the chronic disease sector, emphasizing a multi-faceted approach to managing common chronic conditions through a combination of single and combination therapies [5]. - The company plans to expand its offerings with over 40 new products and indications in various chronic disease areas, enhancing its treatment matrix from generic to specialty drugs [5]. Group 5: Collaborative and Technological Innovations - The establishment of a tiered healthcare system has expanded chronic disease management from hospitals to community and home settings, but challenges remain in addressing diverse patient needs and resource allocation [7]. - AstraZeneca is leveraging technology, such as AR-assisted lung function testing, to improve screening and treatment efficiency, thereby enhancing the management of respiratory diseases [8]. Group 6: Future Directions in Chronic Disease Management - The industry is undergoing a transformation from a disease-centered approach to a patient-centered model, emphasizing the importance of understanding and responding to unmet patient needs [9]. - The future competitiveness in chronic disease management will depend on the ability to innovate scientifically and collaboratively, creating new value propositions in the healthcare ecosystem [9].